Can Nutraceuticals Support the Treatment of MASLD/MASH, and thus Affect the Process of Liver Fibrosis?
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25105238 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Aneta Sokal-Dembowska und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Health Sciences, Medical College, Rzeszow University, 35-959 Rzeszow, Poland. Hauptthemen laut MEDLINE: Dietary Supplements, Liver Cirrhosis. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 177 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Currently, metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) are considered to be the main causes of fibrosis. In turn, fibrosis may lead to the development of hepatocellular carcinoma or advanced cirrhosis, i.e., potentially life-threatening conditions. It is likely that therapy aimed at reducing the risk of developing hepatic steatosis and inflammation could be helpful in minimizing the threat/probability of organ fibrosis. In recent years, increasing attention has been paid to the influence of nutraceuticals in the prevention and treatment of liver diseases. Therefore, the aim of this review was to describe the precise role of selected ingredients such as vitamin C, beta-carotene, omega-3 fatty acids, and curcumin. It is likely that the use of these ingredients in the treatment of patients with MASLD/MASH, along with behavioral and pharmacological therapy, may have a beneficial effect on combating inflammation, reducing oxidative stress, and thereby preventing liver damage.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Health Sciences, Medical College, Rzeszow University, 35-959 Rzeszow, Poland.
- Institute of Medicine, Medical College, Rzeszow University, 35-959 Rzeszow, Poland.
- Department of Gastroenterology with IBD Unit, Clinical Hospital No. 2, 35-301 Rzeszow, Poland.
ORCID-Profile: Aneta Sokal-Dembowska, Sara Jarmakiewicz-Czaja, Katarzyna Ferenc, Rafał Filip
Zitieren
APA
Sokal-Dembowska, A., Jarmakiewicz-Czaja, S., Ferenc, K., & Filip, R. (2024). Can Nutraceuticals Support the Treatment of MASLD/MASH, and thus Affect the Process of Liver Fibrosis?. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25105238
Vancouver
Sokal-Dembowska A, Jarmakiewicz-Czaja S, Ferenc K, Filip R. Can Nutraceuticals Support the Treatment of MASLD/MASH, and thus Affect the Process of Liver Fibrosis?. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25105238
BibTeX
@article{SokalDembowska2024,
author = {Sokal-Dembowska, Aneta and Jarmakiewicz-Czaja, Sara and Ferenc, Katarzyna and Filip, Rafał},
title = {Can Nutraceuticals Support the Treatment of MASLD/MASH, and thus Affect the Process of Liver Fibrosis?},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25105238}
}
EUVIMED